Li Chao, Yang Li, Wu Hongfei, Dai Min
School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.
Key Laboratory of Xin'an Medicine, Ministry of Education, Hefei, China.
Front Pharmacol. 2018 Feb 8;9:95. doi: 10.3389/fphar.2018.00095. eCollection 2018.
Paeonol from Cortex Moutan root is a potential therapeutic agent for atherosclerosis (AS). However, its mechanisms of action are still not fully understood. Vascular endothelial cells (VECs) autophagy plays a vital role in the initiation and progression of AS. In this study, we aim to investigate whether the protective effect of paeonol on ox-LDL-induced VECs injury by regulating autophagy. To address this question, we used ox-LDL-induced rat VECs as a model system to elucidate the protective effect of paeonol on VECs injury. This study displayed that ox-LDL (100 mg/L) treatment inhibited VEC growth in dose- and time-dependent manners, paeonol (60 μM) shown potential in inhibiting ox-LDL-induced death. Furthermore, paeonol significantly reduced ox-LDL-induced the formation of autophagy vacuoles and the expression of LC3II in VECs. Further double-luciferase reporter assay shown that miR-30a specifically binds to the 3'-UTR of Beclin-1 mRNA in VECs. Moreover, we found that ox-LDL decreased miR-30a and increased Beclin-1 expression, pretreatment with paeonol could reverse the process of regulation in dose-dependent manners. In ox-LDL treated VECs, transfection with a miR-30a mimic significantly increased miR-30a expression and inhibited Beclin-1 and LC3II expression, thus enhanced the protective effects of paeonol. Whereas transfection with a miR-30a inhibitor significantly decreased miR-30a expression and increased Beclin-1 and LC3II expression, thus attenuated the protective effects of paeonol. In conclusion, this study has, for the ?rst time, highlighted that miR-30a might be a critical target of paeonol against ox-LDL-induced VECs injury by inhibiting excessive autophagy. Paeonol may be one of promising candidate drug for treatment of AS.
牡丹皮中的丹皮酚是一种潜在的动脉粥样硬化(AS)治疗药物。然而,其作用机制仍未完全明确。血管内皮细胞(VECs)自噬在AS的发生和发展中起着至关重要的作用。在本研究中,我们旨在探讨丹皮酚是否通过调节自噬对氧化型低密度脂蛋白(ox-LDL)诱导的VECs损伤具有保护作用。为解决这个问题,我们使用ox-LDL诱导的大鼠VECs作为模型系统来阐明丹皮酚对VECs损伤的保护作用。本研究表明,ox-LDL(100 mg/L)处理以剂量和时间依赖性方式抑制VEC生长,丹皮酚(60 μM)显示出抑制ox-LDL诱导的细胞死亡的潜力。此外,丹皮酚显著减少ox-LDL诱导的VECs中自噬空泡的形成和微管相关蛋白1轻链3II(LC3II)的表达。进一步的双荧光素酶报告基因检测表明,微小RNA-30a(miR-30a)特异性结合VECs中自噬相关蛋白1(Beclin-1)mRNA的3'-非翻译区(3'-UTR)。此外,我们发现ox-LDL降低miR-30a表达并增加Beclin-1表达,丹皮酚预处理可呈剂量依赖性地逆转这种调节过程。在ox-LDL处理的VECs中,转染miR-30a模拟物可显著增加miR-30a表达并抑制Beclin-1和LC3II表达,从而增强丹皮酚的保护作用。而转染miR-30a抑制剂可显著降低miR-30a表达并增加Beclin-1和LC3II表达,从而减弱丹皮酚的保护作用。总之,本研究首次强调miR-30a可能是丹皮酚通过抑制过度自噬对抗ox-LDL诱导的VECs损伤的关键靶点。丹皮酚可能是治疗AS的有前景的候选药物之一。